Results 111 to 120 of about 128,191 (326)

Perigraftitis treatment and histology: A case report

Clinical Advances in Periodontics, EarlyView.
Abstract Background Currently, the two diagnoses of inflammatory peri‐implant diseases are peri‐implant mucositis and peri‐implantitis. The etiology of peri‐implant mucositis and peri‐implantitis is bacterial colonization of the implant. Thus, removal of the implant should eliminate the infection and allow the inflammation to resolve. However, at least
Jonathan H. Do, Charles M. Cobb, John T. Shen   +2 more
wiley   +1 more source

BCGiosis as a presenting feature of a child with chronic granulomatous disease

Brazilian Journal of Infectious Diseases
Bacillus Calmette Guerin (BCG) vaccine, which is administered to all newborns in some regions, could lead to serious complication ranging from local disease (known as BCGitis) to disseminated disease (BCGosis) in a group of patients with primary ...
Zahra Movahedi, Sayna Norouzi, Setareh Mamishi, Nima Rezaei   +3 more
doaj   +1 more source

Granulomatous Osteonecrosis in Crohn’s Disease

Canadian Journal of Gastroenterology, 2000
A 25-year-old white woman was diagnosed with Crohn’s disease involving the small and large intestines. She had a complex clinical course that required treatment with multiple pharmacological agents, including intravenous, oral and rectal corticosteroids.
Hugh J Freeman, David Owen, Mario Millan
doaj   +1 more source

Granulomatous infiltration of a parathyroid adenoma presenting as primary hyperparathyroidism in a woman: a case report

Journal of Medical Case Reports, 2010
Introduction Hypercalcemia can be associated with vitamin D (1,25(OH)2D3) -mediated granulomatous disorders in addition to primary hyperparathyroidism (PHPT).
Algün Ekrem, Livaoğlu Ayten, Şiviloğlu Çiğdem, Anaforoğlu İnan   +3 more
doaj   +1 more source

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, EarlyView.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Etiological profile and main imaging findings in patients with granulomatous diseases who underwent lung biopsy

, 2021
Camila Vilela de Oliveira, Natally Horvat, Leonardo de Abreu Testagrossa, Davi dos Santos Romão, Marina Bastos Rassi, Hye Ju Lee   +5 more
openalex   +1 more source

Granulomatous lung disease.

Pathologica, 2010
Granulomas are a frequent challenge for pathologists, which can be identified both in histological and cytological material in a number of conditions. With regard to interstitial lung diseases, granulomas can be associated with infection (e.g. mycobacterial), immunological conditions (e.g.
Cancellieri, A, Dalpiaz, G, Trisolini, R, Ricchiuti, E, Pesci, A   +4 more
openaire   +3 more sources

Prognostic role of high‐sensitivity cardiac troponin T in patients with cardiac sarcoidosis: insights from ILLUMINATE‐CS

ESC Heart Failure, Volume 12, Issue 2, Page 869-878, April 2025.
Abstract Aims The prognostic role of high‐sensitivity cardiac troponin T (hs‐cTnT) as a biomarker in patients with cardiac sarcoidosis (CS) has yet to be fully determined, especially when compared with B‐type natriuretic peptide (BNP). Methods and Results In this post‐hoc analysis of the ILLUMINATE‐CS (ILLUstration of the Management and prognosIs of ...
Yuichi Baba, Toru Kubo, Takeru Nabeta, Yuya Matsue, Takeshi Kitai, Yoshihisa Naruse, Tatsunori Taniguchi, Hidekazu Tanaka, Takahiro Okumura, Kenji Yoshioka, Hiroaki Kitaoka   +10 more
wiley   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Editorial: Novel Insights Into the Immunology of Pulmonary Granulomatous Diseases

Frontiers in Immunology, 2021
Mary Jane Thomassen, Marc A. Judson, Barbara P. Barna   +2 more
doaj   +1 more source